FY2025 EPS Estimates for Pfizer Raised by Leerink Partnrs

Pfizer Inc. (NYSE:PFE) – Equities researchers at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for Pfizer in a research note issued to investors on Tuesday, November 4th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $3.11 per share for the year, up from their previous forecast of $3.04. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2026 earnings at $3.20 EPS, FY2027 earnings at $3.16 EPS, FY2028 earnings at $2.57 EPS and FY2029 earnings at $2.24 EPS.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS.

Other equities analysts have also recently issued reports about the stock. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Morgan Stanley cut their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.18.

Pfizer Trading Up 1.3%

PFE stock opened at $24.92 on Friday. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.69. The stock has a market capitalization of $141.68 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm’s fifty day simple moving average is $24.75 and its two-hundred day simple moving average is $24.34.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s payout ratio is 91.49%.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Cidel Asset Management Inc. grew its holdings in Pfizer by 2.6% during the 3rd quarter. Cidel Asset Management Inc. now owns 78,767 shares of the biopharmaceutical company’s stock worth $2,007,000 after acquiring an additional 1,990 shares in the last quarter. Murphy & Mullick Capital Management Corp boosted its stake in shares of Pfizer by 15.8% during the third quarter. Murphy & Mullick Capital Management Corp now owns 13,482 shares of the biopharmaceutical company’s stock valued at $333,000 after purchasing an additional 1,840 shares in the last quarter. MSH Capital Advisors LLC increased its holdings in Pfizer by 23.0% during the third quarter. MSH Capital Advisors LLC now owns 53,682 shares of the biopharmaceutical company’s stock valued at $1,368,000 after buying an additional 10,050 shares during the period. WJ Financial Advisors LLC bought a new position in Pfizer in the third quarter worth approximately $297,000. Finally, Omnia Family Wealth LLC lifted its holdings in Pfizer by 15.3% during the third quarter. Omnia Family Wealth LLC now owns 11,667 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 1,548 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.